^British national formulary : BNF 69 69. British Medical Association. 2015: 579. ISBN 9780857111562.
^World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
^Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leukemia & Lymphoma. July 2007, 48 (7): 1299–1306. PMID 17613757. S2CID 2381354. doi:10.1080/10428190701361828.
^Ozegowski W, Krebs D. Aminosäureantagonisten. III. ω-[Bis-(β-chloräthyl)-amino-benzimidazolyl-(2)]-propion- bzw. -buttersäuren als potentielle Cytostatika. Advanced Synthesis and Catalysis. June 1963, 20 (3–4): 178–186. doi:10.1002/prac.19630200310.
^Lagos GG, Lentzsch S, Comenzo RL, Zonder JA, Osman K, Gould J, Tsai WY, Pregja S, Reyna M, Raza S, Sanchorawala V. Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study. Blood. 2017-12-08,. 130 (supplement 1): 1838.